Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.71 |
| ▸ | KDR | P35968 | 5/20 | 0.71 |
| ▸ | FLT4 | P35916 | 3/20 | 0.71 |
| ▸ | BRAF | P15056 | 2/20 | 0.71 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.71 |
| ▸ | SRC | P12931 | 2/20 | 0.71 |
| ▸ | CIT | O14578 | 1/20 | 0.71 |
| ▸ | GAK | O14976 | 1/20 | 0.71 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.71 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.71 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.71 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.71 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.71 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.71 |
| ▸ | STK17B | O94768 | 1/20 | 0.71 |
| ▸ | STK10 | O94804 | 1/20 | 0.71 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.71 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.71 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22594686 | 0.84 | KDR (0.70) | EGFRKDRFLT4BRAFERBB2 | |
| Gefitinib SCHEMBL29351336 | 0.83 | EGFR (1.00) | EGFRKDRFLT4BRAFERBB2 | |
| Gefitinib SCHEMBL7866 | 0.83 | EGFR (1.00) | EGFRKDRFLT4BRAFERBB2 | |
| Gefitinib SCHEMBL29351046 | 0.83 | EGFR (1.00) | EGFRKDRFLT4BRAFERBB2 | |
| Gefitinib SCHEMBL465143 | 0.83 | EGFR (1.00) | EGFRKDRFLT4BRAFERBB2 | |
| SCHEMBL1734701 | 0.83 | EGFR (1.00) | EGFRKDRFLT4BRAFERBB2 | |
| SCHEMBL13284238 | 0.83 | EGFR (0.91) | EGFRKDRFLT4BRAFERBB2 | |
| SCHEMBL23258972 | 0.82 | EGFR (0.80) | EGFRKDRFLT4BRAFERBB2 | |
| Gefitinib SCHEMBL2770155 | 0.82 | EGFR (0.98) | EGFRKDRFLT4BRAFERBB2 | |
| Gefitinib SCHEMBL30887946 | 0.82 | EGFR (0.98) | EGFRKDRFLT4BRAFERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753431-B2 | Compounds comprising cleavable linker and uses thereof | INTOCELL, INC. (KR) | 2023-09-12 | — | — | US | disclosed |
| US-20100143295-A1 | QUINAZOLINE INHIBITORS OF EGFR TYROSINE KINASE | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100143295-A1 | QUINAZOLINE INHIBITORS OF EGFR TYROSINE KINASE | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143295-A1 | QUINAZOLINE INHIBITORS OF EGFR TYROSINE KINASE | EGFR, ABL1, ERBB2 | EGFR 1/4885KDR 82/4885FLT4 109/4885 |
| US-11753431-B2 | Compounds comprising cleavable linker and uses thereof | VIP, ANTXR2, TNFRSF9 | EGFR 18/4885KDR 421/4885FLT4 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.